MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations • California
THIS MANAGEMENT SERVICES AGREEMENT (this “Agreement”), effective as of October 1, 2014 (the “Effective Date”), is by and between KURA ONCOLOGY, INC., a Delaware corporation (“Kura”), and ARAXES PHARMA LLC, a Delaware limited liability company (the “Company”).
SERVICES AGREEMENTServices Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations • California
THIS SERVICES AGREEMENT (this “Agreement”), effective as of October 1, 2014 (the “Effective Date”), is by and between, WELLSPRING BIOSCIENCES LLC, a Delaware limited liability corporation (“Wellspring”), and KURA ONCOLOGY, INC., a Delaware corporation (the “Company”).
AMENDED AND RESTATED ASSET PURCHASE AGREEMENTAsset Purchase Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations • California
This Amended And Restated Asset Purchase Agreement (the “Agreement”) is entered into as of February 12, 2015 (“Signing Date”), by and between Kura Oncology, Inc., a Delaware corporation (“Purchaser”), and Araxes Pharma LLC, a Delaware limited liability company (“Seller”). The foregoing may be referred to individually as a “Party” and collectively as “Parties” in this Agreement.
Kura Oncology, Inc. Amendment to Amended and Restated Executive Employment Agreement for Troy E. Wilson, Ph.D., J.D.Employment Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations
This Amendment to Amended and Restated Executive Employment Agreement (the “Agreement”), entered into between Kura Oncology, Inc. (the “Company”) and Troy E. Wilson, Ph.D., J.D. (the “Executive”) (collectively, the “Parties”), is effective as of February 19, 2021 (the “Effective Date”).
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations • California
This Master Collaboration Agreement (this “Agreement”) is effective as of January 4, 2021 (the “Effective Date”) and is made by and between Illumina, Inc., a Delaware corporation (“Illumina”) and Kura Oncology, Inc., a Delaware corporation (“Partner”). Illumina and Partner may be referred to each individually as a “Party” and collectively as the “Parties.”
PATENT LICENSE AGREEMENTStock Issuance Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations • Delaware
Milestone payments are non-refundable and non-creditable against future royalties. In the event a SUBLICENSEE pays LICENSEE a fee for achieving one of the milestone events listed above or a substantially similar milestone, LICENSEE shall pay the higher of: (i) the Milestone Payment in this Paragraph 3.1(f) or (ii) the fee due on such Milestone Payment pursuant to Paragraph 3.1(c), but not both.
LICENSE AGREEMENTLicense Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations • New York
shall pay by wire transfer the amount listed in each invoice to Janssen to the bank account identified in Section 7. If any Third Party Sublicense monetary compensation received by Company is in a currency other than US Dollars, the payment due under this Section 6.2(d) shall be calculated in such currency and then converted into their US Dollar equivalent using the closing exchange rate as published by The Wall Street Journal, Western U.S. Edition for the day the Third Party Sublicense compensation was achieved by Company.
FIFTH AMENDMENT TO PATENT LICENSE AGREEMENTPatent License Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations
This FIFTH AMENDMENT TO PATENT LICENSE AGREEMENT (“Amendment”) is entered into as of May 24, 2017 (the “Amendment Effective Date”) by and between Kura Oncology, Inc. (“Licensee”) having the address set forth in Article 12 of the Agreement (as defined below), and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (“Michigan”).
